SMFR SEMA4 HLDGS CORP

GeneDx to Participate in 44th Annual Cowen Health Care Conference

GeneDx to Participate in 44th Annual Cowen Health Care Conference

STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA. Management will participate in a fireside chat on Wednesday, March 6, 2024, at 10:30 a.m. ET.

A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It all starts with a single test. For more information, please visit and connect with us on , , and

GeneDx Investor Relations Contact:

GeneDx Media Contact:



EN
26/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEMA4 HLDGS CORP

 PRESS RELEASE

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, Jul...

GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024  STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024. Management will host a conference call that day to discuss second quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.  Conference Call Details Investors interested in listening to the conference call are required ...

 PRESS RELEASE

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapi...

GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients -- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) -- STAMFORD, Conn., June 10, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insig...

 PRESS RELEASE

GeneDx Announces Patient Access Program to Expand Access to Exome Test...

GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the first-of-its-kind patient access program, developed in partnership with leading biopharma companies, which aims to increase access to exome sequencing for pediatric epilepsy patients. “Receiving a genetic diagnosis can be critical in a child’s journey toward effective treatment and care, and we are thrilled our biopha...

 PRESS RELEASE

GeneDx to Participate in Upcoming Investor Conferences

GeneDx to Participate in Upcoming Investor Conferences STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in two upcoming investor conferences in June: Jefferies Healthcare Conference - New York City, New York Fireside chat on Wednesday, June 5 at 9:00 a.m. ET44th Annual Goldman Sachs Global Healthcare Conference - Miami, Florida Fireside chat on Monday, June 10 at 3:20 p.m. ET Live and archived webcasts of the presentation will be avail...

 PRESS RELEASE

GeneDx Reports First Quarter 2024 Financial Results and Business Highl...

GeneDx Reports First Quarter 2024 Financial Results and Business Highlights Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss2 to $8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and $245M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMF...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch